| Literature DB >> 15233937 |
Claudia Rossig1, Malcolm K Brenner.
Abstract
Adoptive transfer of T lymphocytes is a promising therapy for malignancies-particularly of the hemopoietic system-and for otherwise intractable viral diseases. Efforts to broaden the approach have been limited by the physiology of the T cells themselves and by a range of immune evasion mechanisms developed by tumor cells. In this review we show how genetic modification of T cells is being used preclinically and in patients to overcome these limitations, by incorporation of novel receptors, resistance mechanisms, and control genes. We also discuss how the increasing safety and effectiveness of gene transfer technologies will lead to an increase in the use of gene-modified T cells for the treatment of a wider range of disorders.Entities:
Mesh:
Year: 2004 PMID: 15233937 DOI: 10.1016/j.ymthe.2004.04.014
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454